These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31635555)

  • 1. Clinical characteristics and risk factors of microvascular involvement in primary antiphospholipid syndrome: a longitudinal single-center study in China.
    Sun Y; Zhao J; Zhang P; Wu C; Jiang N; Zhou J; Zhang S; Wu Q; Wang Q; Li M; Zeng X
    Lupus; 2019 Nov; 28(13):1558-1565. PubMed ID: 31635555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical manifestations and thrombotic risk factors in primary antiphospholipid syndrome].
    Zhao JL; Sun YD; Zhang Y; Xu D; Wang Q; Li MT; Zeng XF
    Zhonghua Nei Ke Za Zhi; 2016 May; 55(5):386-91. PubMed ID: 27143190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
    J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study.
    Saccone G; Berghella V; Maruotti GM; Ghi T; Rizzo G; Simonazzi G; Rizzo N; Facchinetti F; Dall'Asta A; Visentin S; Sarno L; Xodo S; Bernabini D; Monari F; Roman A; Eke AC; Hoxha A; Ruffatti A; Schuit E; Martinelli P;
    Am J Obstet Gynecol; 2017 May; 216(5):525.e1-525.e12. PubMed ID: 28153662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of risk factors in development of thrombosis in patients with antiphospholipid syndrome].
    Li R; Zhou YS; Jia Y; Li ZG
    Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Oct; 44(5):788-91. PubMed ID: 23073594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The clinical manifestations and risk factors in primary antiphospholipid syndrome with thrombocytopenia].
    Li S; Lan XL; Cai HC; Zhu TN; Wang SJ; Zhao YQ
    Zhonghua Xue Ye Xue Za Zhi; 2021 Jan; 42(1):33-38. PubMed ID: 33677866
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody profiles for the diagnosis of antiphospholipid syndrome.
    Pengo V; Biasiolo A; Pegoraro C; Cucchini U; Noventa F; Iliceto S
    Thromb Haemost; 2005 Jun; 93(6):1147-52. PubMed ID: 15968401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study.
    Zuily S; Regnault V; Guillemin F; Kaminsky P; Rat AC; Lecompte T; Wahl D
    Thromb Res; 2013 Jul; 132(1):e1-7. PubMed ID: 23676348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Following 90 patients with antiphospholipid syndrome with antibody titers and correlations with clinical manifestations: symptoms of the disease, a new antibody and correlations with clinical manifestations in the Israeli population].
    Marai I; Levi Y; Godard G; Shoenfeld Y
    Harefuah; 2001 Jun; 140(6):495-500, 565. PubMed ID: 11420848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome.
    Figueredo MA; Rodriguez A; Ruiz-Yagüe M; Romero M; Fernandez-Cruz A; Gomez-de la Concha E; Patiño R
    J Rheumatol; 2006 Oct; 33(10):1980-6. PubMed ID: 17014014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of anti-domain 1 β2-glycoprotein I antibodies in antiphospholipid syndrome.
    Iwaniec T; Kaczor MP; Celińska-Löwenhoff M; Polański S; Musiał J
    Thromb Res; 2017 May; 153():90-94. PubMed ID: 28363116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical features and risk factors of portal vein thrombosis in 28 patients with antiphospholipid syndrome].
    You HX; Zhao JL; Wang Q; Tian XP; Li MT; Zeng XF
    Zhonghua Nei Ke Za Zhi; 2019 Dec; 58(12):894-898. PubMed ID: 31775452
    [No Abstract]   [Full Text] [Related]  

  • 13. IgA anticardiolipin and IgA anti-β2 glycoprotein I antibody positivity determined by fluorescence enzyme immunoassay in primary antiphospholipid syndrome.
    Mattia E; Ruffatti A; Tonello M; Meneghel L; Robecchi B; Pittoni M; Gallo N; Salvan E; Teghil V; Punzi L; Plebani M
    Clin Chem Lab Med; 2014 Sep; 52(9):1329-33. PubMed ID: 24651022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anatomic distribution of venous thrombosis in patients with antiphospholipid antibody: imaging findings.
    Provenzale JM; Ortel TL
    AJR Am J Roentgenol; 1995 Aug; 165(2):365-8. PubMed ID: 7618558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent thrombocytopenia predicts poor long-term survival in patients with antiphospholipid syndrome: a 38-year follow-up study.
    Pardos-Gea J; Marques-Soares JR; Buján S; Ordi-Ros J; Alijotas-Reig J
    Rheumatology (Oxford); 2022 Mar; 61(3):1053-1061. PubMed ID: 34115832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombocytopenia as a thrombotic risk factor in patients with antiphospholipid antibodies without disease criteria.
    Demetrio Pablo R; Muñoz P; López-Hoyos M; Calvo V; Riancho L; Martínez-Taboada VM
    Med Clin (Barc); 2017 May; 148(9):394-400. PubMed ID: 28153433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study.
    Mustonen P; Lehtonen KV; Javela K; Puurunen M
    Lupus; 2014 Dec; 23(14):1468-76. PubMed ID: 25164304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
    Cervera R; Serrano R; Pons-Estel GJ; Ceberio-Hualde L; Shoenfeld Y; de Ramón E; Buonaiuto V; Jacobsen S; Zeher MM; Tarr T; Tincani A; Taglietti M; Theodossiades G; Nomikou E; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Fernández-Nebro A; Haro M; Amoura Z; Miyara M; Tektonidou M; Espinosa G; Bertolaccini ML; Khamashta MA;
    Ann Rheum Dis; 2015 Jun; 74(6):1011-8. PubMed ID: 24464962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for arterial thrombosis in antiphospholipid syndrome.
    Matyja-Bednarczyk A; Swadźba J; Iwaniec T; Sanak M; Dziedzina S; Ćmiel A; Musiał J
    Thromb Res; 2014 Feb; 133(2):173-6. PubMed ID: 24321419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome.
    Warkentin TE; Aird WC; Rand JH
    Hematology Am Soc Hematol Educ Program; 2003; ():497-519. PubMed ID: 14633796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.